Related Experiment Video
Updated: May 23, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Condensates as a Culprit in RAS Activation and Inhibitor Resistance
Hannah C Bergo1,2,3, Logan B Leak1,2,3, Trever G Bivona1,2,3,4
1Department of Medicine, University of California, San Francisco, San Francisco, California.
Abstract:
Therapy resistance is a significant cause of death in patients treated with targeted cancer therapy in diverse oncogene-driven cancers. A better understanding of resistance mechanisms can lay the foundation for improving existing and developing new therapies. A recent elegant study published in Nature Chemical Biology sheds light on a new resistance mechanism. The authors define a novel role for ARAF, a member of the RAF protein family (ARAF, BRAF, and CRAF), that is distinct from its previously understood role as a RAS effector and MEK protein kinase in the MAPK pathway. They describe how ARAF sequesters active RAS at the plasma membrane in phase-separated condensates to sustain signaling and prevent inactivation by the RAS GTPase-activating protein neurofibromin 1. This study underscores emerging roles for biomolecular condensates in cancer and highlights important implications for disrupting protein condensates to address treatment resistance to RAS (and RAS pathway)-targeted therapies. The study also illuminates evolutionary functional distinction between the RAF proteins and indicates unique biology for ARAF in normal physiology and disease.
Insights
ARAF protein forms novel condensates that sustain RAS signaling, driving therapy resistance in cancers. Targeting these ARAF-RAS condensates may overcome resistance to RAS-targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Therapy resistance is a major cause of mortality in oncogene-driven cancers.
- Understanding resistance mechanisms is crucial for developing effective cancer treatments.
Purpose of the Study:
- To elucidate a novel resistance mechanism in targeted cancer therapy.
- To investigate the role of ARAF in RAS-mediated signaling and therapy resistance.
Main Methods:
- Investigated the function of ARAF in RAS signaling.
- Utilized techniques to study protein interactions and localization.
- Examined the role of ARAF in phase-separated condensates.
Main Results:
- ARAF sequesters active RAS in phase-separated condensates at the plasma membrane.
- This sequestration sustains MAPK pathway signaling and prevents RAS inactivation by neurofibromin 1.
- ARAF exhibits a distinct biological role compared to other RAF proteins.
Conclusions:
- ARAF plays a novel role in sustaining RAS signaling through biomolecular condensates.
- This mechanism contributes to therapy resistance in RAS-driven cancers.
- Targeting ARAF-mediated condensates presents a potential strategy to overcome treatment resistance.
More Related Videos
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
MAPK Signaling Cascades
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...